(RTTNews) - Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of ...
The summary covers major health news, including six transplant patients in Brazil contracting HIV from infected organs, ...
Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII ...
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...
Recent health developments include HIV infections from organ transplants in Brazil, Sanofi's potential sale of a stake in its ...
The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...
The FDA has approved Pfizer’s marstacimab under the brand name Hympavzi for adults and children with hemophilia A or B, ...
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
Animal rights activists are risking their lives in Lebanon to rescue cats, dogs and other animals harmed by Israeli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback